uniQure (QURE) Competitors $15.50 +0.03 (+0.16%) As of 02:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QURE vs. MTSR, MIRM, MENS, KYMR, SRRK, BHC, XENE, AMRX, HCM, and RAREShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Metsera (MTSR), Mirum Pharmaceuticals (MIRM), Jyong Biotech (MENS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Bausch Health Cos (BHC), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), HUTCHMED (HCM), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. uniQure vs. Its Competitors Metsera Mirum Pharmaceuticals Jyong Biotech Kymera Therapeutics Scholar Rock Bausch Health Cos Xenon Pharmaceuticals Amneal Pharmaceuticals HUTCHMED Ultragenyx Pharmaceutical Metsera (NASDAQ:MTSR) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings. Do insiders & institutionals believe in MTSR or QURE? 78.8% of uniQure shares are owned by institutional investors. 4.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher earnings and valuation, MTSR or QURE? Metsera has higher earnings, but lower revenue than uniQure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetseraN/AN/A-$209.13MN/AN/AuniQure$27.12M31.37-$239.56M-$3.92-3.96 Is MTSR or QURE more profitable? Metsera has a net margin of 0.00% compared to uniQure's net margin of -1,387.98%. Metsera's return on equity of 0.00% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets MetseraN/A N/A N/A uniQure -1,387.98%-1,010.74%-33.27% Does the media favor MTSR or QURE? In the previous week, uniQure had 4 more articles in the media than Metsera. MarketBeat recorded 6 mentions for uniQure and 2 mentions for Metsera. uniQure's average media sentiment score of 2.00 beat Metsera's score of 0.55 indicating that uniQure is being referred to more favorably in the news media. Company Overall Sentiment Metsera Positive uniQure Very Positive Do analysts prefer MTSR or QURE? Metsera currently has a consensus target price of $55.00, indicating a potential upside of 67.63%. uniQure has a consensus target price of $37.45, indicating a potential upside of 141.56%. Given uniQure's higher probable upside, analysts plainly believe uniQure is more favorable than Metsera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metsera 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00uniQure 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummaryuniQure beats Metsera on 8 of the 12 factors compared between the two stocks. Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$846.37M$3.12B$5.76B$9.55BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-3.9320.4630.4325.11Price / Sales31.37237.31392.2187.48Price / CashN/A42.3737.0358.50Price / Book-221.507.959.016.20Net Income-$239.56M-$54.72M$3.26B$265.38M7 Day Performance-1.74%1.56%1.00%-1.25%1 Month Performance6.93%5.71%4.19%-0.81%1 Year Performance120.55%9.01%28.39%18.83% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure2.8388 of 5 stars$15.51+0.2%$37.45+141.6%+128.3%$846.37M$27.12M-3.93500Analyst RevisionMTSRMetseraN/A$32.39+4.0%$55.00+69.8%N/A$3.40BN/A0.0081News CoverageMIRMMirum Pharmaceuticals3.4575 of 5 stars$66.68-1.8%$74.13+11.2%+62.7%$3.35B$336.89M-55.11140MENSJyong BiotechN/A$41.50-7.2%N/AN/A$3.16BN/A0.0031KYMRKymera Therapeutics3.0188 of 5 stars$43.62+2.3%$59.11+35.5%-8.9%$3.12B$47.07M-12.57170SRRKScholar Rock4.4071 of 5 stars$31.52+0.4%$45.14+43.2%+269.1%$3.03B$33.19M-10.83140News CoverageAnalyst ForecastBHCBausch Health Cos4.3097 of 5 stars$8.02-3.8%$9.00+12.2%+30.3%$2.97B$9.63B30.8520,700XENEXenon Pharmaceuticals2.0502 of 5 stars$37.82-1.1%$53.20+40.7%-4.7%$2.92B$9.43M-10.65210Options VolumeAnalyst RevisionAMRXAmneal Pharmaceuticals3.2243 of 5 stars$9.26-2.0%$11.60+25.3%+16.2%$2.91B$2.79B926.938,100HCMHUTCHMED2.6791 of 5 stars$16.43-0.1%$28.00+70.4%-11.6%$2.87B$630.20M0.001,811RAREUltragenyx Pharmaceutical4.6402 of 5 stars$29.70+0.0%$81.50+174.4%-44.6%$2.86B$560.23M-5.371,294 Related Companies and Tools Related Companies MTSR Alternatives MIRM Alternatives MENS Alternatives KYMR Alternatives SRRK Alternatives BHC Alternatives XENE Alternatives AMRX Alternatives HCM Alternatives RARE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QURE) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access